Scarica l'app Stockscreener
41.63
1.28%
-0.54
Dopo l'orario di chiusura:
41.63
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Real time pattern detection on Xenon Pharmaceuticals Inc. stock2025 Earnings Surprises & Long-Term Investment Growth Plans - newser.com
Will Xenon Pharmaceuticals Inc. stock attract ESG investorsIPO Watch & Precise Buy Zone Tips - Trung tâm Dự báo KTTV quốc gia
Options Flow: Is Xenon Pharmaceuticals Inc. stock attractive for income investorsWeekly Investment Recap & Technical Pattern Based Buy Signals - Trung tâm Dự báo KTTV quốc gia
Will Xenon Pharmaceuticals Inc. price bounce be sustainable2025 Fundamental Recap & Smart Allocation Stock Tips - newser.com
Xenon Pharmaceuticals Appoints Tucker Kelly as CFO to Drive Commercialization Efforts - The Globe and Mail
Can a trend reversal in Xenon Pharmaceuticals Inc. lead to recoveryQuarterly Portfolio Report & Verified Momentum Watchlists - newser.com
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer - GlobeNewswire
Xenon Pharmaceuticals Inc. Announces Appointment of Tucker Kelly as Member of Its Senior Executive Team - MarketScreener
Xenon Pharmaceuticals Inc. Appoints Tucker Kelly as Chief Financial Officer to Advance Commercialization of Azetukalner - Quiver Quantitative
225,000-Share Option: Xenon Appoints Tucker Kelly as CFO with 30,000 RSUs preparing for topline data - Stock Titan
Xenon Pharmaceuticals’ (XENE) Sell (D-) Rating Reaffirmed at Weiss Ratings - Defense World
Investors Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Visualizing Xenon Pharmaceuticals Inc. stock with heatmapsJuly 2025 Catalysts & Capital Efficiency Focused Strategies - newser.com
Why Xenon Pharmaceuticals Inc. stock is trending among retail tradersWeekly Trade Report & Low Risk Investment Opportunities - newser.com
Is Xenon Pharmaceuticals Inc a good long term investmentTechnology Stock Trends & Minimal Capital Trading Tips - earlytimes.in
Xenon Pharmaceuticals Inc.’s volatility index tracking explained2025 AllTime Highs & Low Drawdown Investment Ideas - newser.com
Will Xenon Pharmaceuticals Inc. stock maintain growth storyPortfolio Return Report & Technical Confirmation Trade Alerts - newser.com
Published on: 2025-10-13 08:53:34 - newser.com
Mirae Asset Global Investments Co. Ltd. Purchases 403 Shares of Xenon Pharmaceuticals Inc. $XENE - Defense World
Will Xenon Pharmaceuticals Inc. stock attract more institutional investorsWeekly Trade Recap & Entry Point Confirmation Alerts - newser.com
Xenon Pharmaceuticals (XENE): Exploring Valuation After Recent Share Price Momentum - Yahoo Finance
Leerink Partners Remains a Buy on Xenon (XENE) - The Globe and Mail
Evaluating Xenon Pharmaceuticals (XENE): Is the Current Valuation Justified After Recent Share Price Momentum? - Sahm
Research Analysts Issue Forecasts for XENE FY2025 Earnings - MarketBeat
What is Bloom Burton’s Estimate for XENE FY2025 Earnings? - Defense World
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - MSN
Is Xenon Pharmaceuticals Inc. stock attractive for income investors2025 Trading Recap & Capital Efficiency Focused Ideas - newser.com
Is Xenon Pharmaceuticals a Smart Investment After Its New Clinical Trial Partnership? - Sahm
What analysts say about Xenon Pharmaceuticals Inc stockInsider Selling Patterns & Budget Friendly Trading Strategies - earlytimes.in
Brokers Offer Predictions for XENE FY2026 Earnings - MarketBeat
Bloom Burton Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Strong-Buy" - MarketBeat
Xenon Pharmaceuticals’ (XENE) Outperform Rating Reaffirmed at William Blair - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Given “Buy” Rating at Chardan Capital - Defense World
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
77,750 Options: Xenon Pharmaceuticals Grants Equity to Seven New Hires at $39.20, Oct 2, 2025 - Stock Titan
Xenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at William Blair - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Receives "Buy" Rating from Chardan Capital - MarketBeat
XENE: Chardan Capital Maintains Buy Rating with $55 Price Target - GuruFocus
Chardan Capital Maintains Xenon Pharmaceuticals (XENE) Buy Recommendation - Nasdaq
Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: Biotechnology Innovator with a 38.93% Upside Potential - DirectorsTalk Interviews
Transcript : Xenon Pharmaceuticals Inc.Special Call - MarketScreener
Will Xenon Pharmaceuticals Inc. stock recover after recent dropJobs Report & Verified Swing Trading Watchlist - newser.com
Is it time to cut losses on Xenon Pharmaceuticals Inc.Market Growth Summary & Safe Capital Investment Plans - newser.com
Xenon Pharmaceuticals Inc. $XENE Shares Purchased by J. Safra Sarasin Holding AG - MarketBeat
Xenon Pharmaceuticals announces executive changes - MSN
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):